Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Zepbound and Wegovy represent two distinct approaches to GLP-1 receptor therapy, yet many people wonder which delivers superior weight loss outcomes. Clinical trials show tirzepatide (Zepbound's active ingredient) produced average weight reductions of 20.7% over 72 weeks, while semaglutide (Wegovy's active ingredient) achieved approximately 14.9% in comparable populations. The choice between them depends on individual metabolic pathways, side effect tolerance, and treatment goals.
How Zepbound and Wegovy Differ at the Cellular Level
Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist that activates two separate hormonal pathways simultaneously. Wegovy contains semaglutide, which activates only the GLP-1 receptor. This fundamental difference means tirzepatide signals the body through two independent channels that regulate appetite, glucose metabolism, and energy expenditure. Semaglutide engages a single channel, which is highly effective but operates through a narrower biological mechanism.
The dual-receptor approach of tirzepatide may explain why some patients experience faster weight loss or sustained results over longer periods. However, individual genetic factors influence how efficiently each receptor pathway functions in any given person. PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R and GIPR genes to identify which receptor pathway may be more active in your metabolism, helping predict whether dual or single-receptor therapy aligns better with your genetic profile.
Clinical Trial Data: Weight Loss Outcomes Compared
In the SURMOUNT-4 trial, tirzepatide delivered an average weight loss of 20.7% at the highest dose after 72 weeks, significantly outperforming semaglutide's 14.9% average from the STEP trials conducted over similar timeframes. These outcomes were measured in populations with comparable baseline body mass indices and metabolic profiles. The superior performance held true across multiple tirzepatide dose levels, with intermediate doses still exceeding semaglutide's highest-dose results. Neither medication produced these outcomes without dietary and exercise modifications, but tirzepatide's dual-pathway activation appeared to amplify the combined effect.
Response variability remains notable—some individuals achieve their goal weight on semaglutide alone, while others require tirzepatide's additional receptor engagement to reach targets. Genetic differences in GLP1R and GIPR expression explain part of this variability. Starting with genetic insight into your receptor pathways allows for more informed medication selection from the beginning of treatment.
Cost, Access, and Treatment Flexibility at PlexusDx
PlexusDx offers compounded tirzepatide injection starting at $249/month, with no insurance requirement, no membership fees, and eligibility for HSA/FSA accounts. Compounded semaglutide injection begins at $149/month. Both formulations come from licensed 503A compounding pharmacies and serve all 50 states, ensuring consistent access regardless of geographic location or insurance status. Pricing remains flat regardless of dose level—your dose may increase as your treatment progresses, but your monthly cost stays the same.
Oral formulations provide an alternative for patients who prefer avoiding injections: oral tirzepatide costs $279/month, while oral semaglutide costs $249/month. PlexusDx also offers a dual-compound GLP-Squared Injection combining semaglutide and tirzepatide in a single weekly injection, starting at $249/month for patients who benefit from additive receptor activation. The Precision Peptide Genetic Test ($99 add-on after the first treatment month) identifies your peptide pathway strengths, allowing personalized medication selection based on your genetic architecture rather than trial-and-error dosing.
Side Effects, Tolerability, and Individual Response Patterns
Both tirzepatide and semaglutide commonly cause gastrointestinal side effects including nausea, vomiting, constipation, and diarrhea, particularly during dose escalation phases. Tirzepatide's dual-pathway activation sometimes produces more pronounced initial nausea in certain individuals, though tolerance typically develops within 2–4 weeks as the body adapts. Semaglutide's single-pathway mechanism may feel gentler for patients with sensitive gastrointestinal systems, making it a reasonable first-line choice for those with prior medication intolerance. Serious adverse events remain rare in clinical populations when medications are properly dosed and monitored.
Genetic factors influence how your body metabolizes and responds to each medication. Variants in the FTO gene (rs9939609) and MC4R gene (rs17782313) affect baseline appetite regulation and may predict which receptor agonist produces optimal satiety with minimal side effects. PlexusDx's genetic testing maps these variants alongside GLP1R and GIPR status, creating a personalized side-effect probability profile before you begin treatment. This data-driven approach reduces the likelihood of starting a medication your body will reject, saving time and money in the long run.
Personalization: Why Genetics Matter in Your Medication Choice
Standard weight loss medicine selection often relies on trial-and-error: start with one medication, assess results and tolerability over weeks, then switch if outcomes disappoint. This approach wastes time during the critical early treatment window when motivation and compliance are highest. PlexusDx's Precision Peptide Genetic Test eliminates guesswork by analyzing 14 metabolic pathways and 49 peptide variants, including the receptors both tirzepatide and semaglutide target. Knowing whether your GLP1R pathway is naturally robust or whether your GIPR pathway shows enhanced activity informs which medication—or combination—will work hardest for your specific biology.
Patients with strong GLP1R baseline expression often succeed with semaglutide alone, while those showing elevated GIPR activity benefit from tirzepatide's dual engagement. Others display genetic patterns suggesting maximum response to GLP-Squared (the dual compound), which activates both pathways simultaneously. Genetic insight transforms weight loss medication from a guessing game into precision medicine, aligning your treatment with your hardwired metabolic strengths rather than population averages. PlexusDx makes this testing available affordably ($99) and integrates results directly into your treatment plan starting month two.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Zepbound actually better than Wegovy for everyone?
No—clinical trials show tirzepatide (Zepbound) produces larger average weight loss than semaglutide (Wegovy), but individual responses vary based on genetics and metabolism. PlexusDx's Precision Peptide Genetic Test identifies whether your GLP1R or GIPR pathways are naturally stronger, predicting which medication will work hardest for your specific biology.
What does the data show about how much weight people lose on each medication?
Tirzepatide achieved 20.7% average weight loss over 72 weeks in clinical trials, while semaglutide achieved approximately 14.9% over similar timeframes. Both results required concurrent lifestyle modifications. Individual outcomes ranged from 5% to over 25% depending on baseline characteristics and adherence.
How much does PlexusDx charge for tirzepatide versus semaglutide?
PlexusDx's compounded tirzepatide injection starts at $249/month flat (dose does not change price), while semaglutide injection starts at $149/month. Both are available for all 50 states with no insurance required, and both qualify for HSA/FSA accounts.
Which medication causes fewer side effects—tirzepatide or semaglutide?
Both commonly cause nausea and gastrointestinal changes. Semaglutide may feel gentler initially for some patients, while tirzepatide's dual-pathway activation sometimes produces stronger early side effects that typically resolve in 2–4 weeks. Genetic variants in FTO and MC4R influence individual side-effect severity, which PlexusDx's genetic test identifies.
How does the Precision Peptide Genetic Test help me choose between Zepbound and Wegovy?
PlexusDx's test analyzes GLP1R and GIPR variants along with 47 other peptide-pathway genes, revealing whether your metabolism favors single or dual-receptor activation. This genetic insight predicts which medication will produce the strongest response with the fewest side effects, personalizing your treatment from day one rather than relying on population averages.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Weight Do You Have to Be for Ozempic?
How to Help Ozempic Nausea: Relief and Management Strategies